EUVIMEDEUVIMED entdecken
Übersichtsarbeit

A Comprehensive Review on the Role of Lurbinectedin in Soft Tissue Sarcomas

Rita Khoury, Tarek Assi, Rebecca Ibrahim, Tony Ibrahim, Benjamin Verret, Clemence Henon, Ratislav Bahleda, Axel Le Cesne

Current Treatment Options in Oncology · 2024

DOI: 10.1007/s11864-024-01178-4 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Treatment Options in Oncology, 2024. Verfasst von Rita Khoury und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of International Patients Care, Gustave Roussy Cancer Campus, 114, Rue Edouard Vaillant, Villejuif, France. Hauptthemen laut MEDLINE: Tetrahydroisoquinolines, Sarcoma, Soft Tissue Neoplasms, Carbolines. Die Arbeit nennt 60 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OPINION STATEMENT: Soft tissue sarcoma (STS), a substantial group of aggressive and rare tumors with tissue heterogeneity, is infrequently represented in clinical trials with an urgent necessity for newer treatment options. Lurbinectedin, an analog of trabectedin, is currently approved, in various countries, as a single agent, for the treatment of patients with relapsed small cell lung cancer (SCLC). However, preclinical and phase I and phase II trials have demonstrated the efficacy of lurbinectedin in different tumor types, including STS. The better understanding of the pathophysiology and evolution of STS as well as the mechanism of action of lurbinectedin in addition to the available data regarding the activity of this drug in this subset of patients will pave the way to newer therapeutic options and strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TetrahydroisoquinolinesSarcomaSoft Tissue NeoplasmsCarbolinesHeterocyclic Compounds, 4 or More RingsHumansAntineoplastic Agents, AlkylatingDioxolesNeoplasm Recurrence, Local

Stichwörter der Autor:innen

CancerLurbinectedinSarcomaSoft tissueTrabectedin

Substanzen

PM 01183TetrahydroisoquinolinesAntineoplastic Agents, AlkylatingDioxolesCarbolinesHeterocyclic Compounds, 4 or More Rings

Autor:innen und Institutionen

  • Division of International Patients Care, Gustave Roussy Cancer Campus, 114, Rue Edouard Vaillant, Villejuif, France.
  • Division of International Patients Care, Gustave Roussy Cancer Campus, 114, Rue Edouard Vaillant, Villejuif, France. Tarek.assi@gustaveroussy.fr.
  • Sarcoma Unit, Gustave Roussy Cancer Campus, 114, Rue Edouard Vaillant, Villejuif, France. Tarek.assi@gustaveroussy.fr.
  • Sarcoma Unit, Gustave Roussy Cancer Campus, 114, Rue Edouard Vaillant, Villejuif, France.

Zitieren

APA

Khoury, R., Assi, T., Ibrahim, R., Ibrahim, T., Verret, B., Henon, C., Bahleda, R., & Le Cesne, A. (2024). A Comprehensive Review on the Role of Lurbinectedin in Soft Tissue Sarcomas. Current Treatment Options in Oncology. https://doi.org/10.1007/s11864-024-01178-4

Vancouver

Khoury R, Assi T, Ibrahim R, Ibrahim T, Verret B, Henon C, et al. A Comprehensive Review on the Role of Lurbinectedin in Soft Tissue Sarcomas. Current Treatment Options in Oncology. 2024. doi:10.1007/s11864-024-01178-4

BibTeX
@article{Khoury2024,
  author = {Khoury, Rita and Assi, Tarek and Ibrahim, Rebecca and Ibrahim, Tony and Verret, Benjamin and Henon, Clemence and Bahleda, Ratislav and Le Cesne, Axel},
  title = {A Comprehensive Review on the Role of Lurbinectedin in Soft Tissue Sarcomas},
  journal = {Current Treatment Options in Oncology},
  year = {2024},
  doi = {10.1007/s11864-024-01178-4}
}
Kostenlos starten →